- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03679780
The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction
Study Overview
Status
Detailed Description
Cardiovascular disease (CVD) afflicts nearly one-third of the adult population with all races and ethnicities represented in CVD prevalence. Unfortunately, a disparity exists such that the black population (BL) is disproportionately affected compared to other groups, including the white population (WH). While the underlying cause of this disparity is multifactorial, vascular dysfunction (i.e., impaired vasodilation and/or augmented vasoconstriction) is a key contributor. Across a series of studies conducted in our laboratory we have consistently observed impaired microvascular function in the small blood vessels in the skin (the cutaneous microvasculature) in AA relative to age, sex, and body mass index Caucasian Americans (CA). From a research design perspective this offers the opportunity to conduct minimally invasive studies while investigating research questions in a systematic and mechanistic manner. Furthermore, the cutaneous circulation is recognized as surrogate vascular bed for assessment of mechanisms underlying systemic vascular disease and microvascular dysfunction is emerging as a critical step in the artherosclerotic process and a variety of conditions including hypertension, exercise intolerance, and insulin resistance. And, impaired cutaneous microvascular function mirrors impaired responses in other vascular beds. A primary advantage to utilizing the cutaneous circulation is that it provides an accessible vascular bed through which processes of endothelial function can be investigated, with virtually no risk, through thermal stimuli and local intra-dermal drug infusions.
In terms of the AA population our group and others have documented that impaired vascular function and elevated disease risk is related, in part, to reductions in bioavailability of the potent vasodilator Nitric oxide (NO). While, this has become fairly common knowledge what remains less well defined is the mechanisms of this reduced NO bioavailability. We have recently identified a role for oxidative stress in this process. However, oxidative stress is a complex process and likely does not explain all of the observed impairment. 2 other possibilities that are attractive candidate targets for mechanistic studies are the endothelin pathway as well as bioavailability of L-Arginine. Endothelin is a hormone that has been implicated in many populations with elevated CVD risk as it is a potent vasoconstrictor which also can reduce NO bioavailability. Interestingly, there are reports of elevated endothelin circulating concentration and/or increased sensitivity and thus vasoconstriction to endothelin in AA. L-Arginine is a naturally occurring amino acid that is required for the full endogenous production of NO. In other words reduced L-Arginine bioavailability is present in many disease conditions and contributes to vascular dysfunction. In regards to AA it is reported that they have reduced natural production of L-arginine and also respond more positively to intra coronary infusion of L-arginine relative to other populations. However, to our knowledge the role of the endothelin system as well as L-arginine in microvascular dysfunction in AA has never been investigated.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: R. Matthew Brothers, PhD
- Phone Number: 8172723156
- Email: matthew.brothers@uta.edu
Study Contact Backup
- Name: John D Akins, MS
- Phone Number: 8172721835
- Email: john.akins@uta.edu
Study Locations
-
-
Texas
-
Arlington, Texas, United States, 76019
- Recruiting
- Science and Engineering Research and Innovation Building
-
Contact:
- R. Matthew Brothers, PhD
- Phone Number: 8172723156
- Email: matthew.brothers@uta.edu
-
Contact:
- John D Akins, MS
- Phone Number: 8172721835
- Email: john.akins@uta.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Individuals (ages 18-35, both genders) will be recruited from the greater Arlington area to participate in the study.
- Must self-report both parents as either African American or Caucasian American.
Exclusion Criteria:
- Individuals who have donated more than 550 ml of blood within the past 8 weeks will not have blood drawn from them in this protocol. However, if they remain interested in the study, and otherwise meet the inclusion criteria, than we may still opt to proceed with data collection.
- Individuals with cardiovascular, neurological, and/or metabolic illnesses will be excluded from participating as well as individuals with a history of various diseases of the microvasculature including Reynaud's disease, cold-induced urticaria, cryoglobulinemia, etc.
- Subjects currently taking any prescription medications and individuals with a body mass index about 30 kg/m2) will be excluded.
- Pregnant subjects and children (i.e. younger than 18) will not be recruited for the study. Eligible females will be scheduled for days 2-7 of their menstrual cycle to account for hormonal effects on blood flow. A regular menstrual cycle is required to identify and schedule the study for the low hormone period, therefore females who lack a regular cycle will be excluded from the study. Females currently taking birth control are eligible, as long as they can be scheduled during a low-hormone "placebo" week. If their hormone do not contain a placebo week than these individuals will not be eligible for data collection. Females who are breast-feeding will also be eligible as there are no systemic or lasting effects of the proposed vasoactive agents.
- Given that smoking can affect the peripheral vasculature, current smokers and individuals who regularly smoked (>1 pack per two weeks) within the prior 2 years will be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control
This site will serve as the control site and will receive lactated Ringer's (saline solution) (2 µl/min) throughout the entire duration of the protocol.
This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
|
L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation.
The infusion rate will be 2 µl/min
Other Names:
SNP will be perfused through each site to induce maximal vasodilation.
The infusion rate will be 2 µl/min
Other Names:
Lactated Ringer will serve as the control site.
The infusion rate will be 2 µl/min
|
Experimental: Inhibitor of Endothelin Type B Receptor
This site will receive 300 nM BQ-788, an inhibitor of the endothelin type B receptors.
This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
|
L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation.
The infusion rate will be 2 µl/min
Other Names:
SNP will be perfused through each site to induce maximal vasodilation.
The infusion rate will be 2 µl/min
Other Names:
This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction.
The infusion rate will be 2 µl/min
|
Experimental: Inhibition of Endothelin Type A Receptor
This site will receive 500 nM aBQ-123, an inhibitor of endothelin type A receptors.
This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
|
L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation.
The infusion rate will be 2 µl/min
Other Names:
SNP will be perfused through each site to induce maximal vasodilation.
The infusion rate will be 2 µl/min
Other Names:
This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction.
The infusion rate will be 2 µl/min
|
Experimental: L-Arginine
This site will receive 10 mM L-Arginine to supplement the substrate for endothelial nitric oxide synthase.
This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
|
L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation.
The infusion rate will be 2 µl/min
Other Names:
SNP will be perfused through each site to induce maximal vasodilation.
The infusion rate will be 2 µl/min
Other Names:
A substrate that is administered to increase endogenous nitric oxide production.
The infusion rate will be 2 µl/min
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vasodilatory Response to Endothelin Receptor-A/B Blockers and L-Arginine following local heating as assessed by Intradermal Microdialysis and Laser Doppler Fluxmetry
Time Frame: Through study completion, an average of 1 Year
|
Determine to what extent overactivation of Endothelin Receptor Type A/B or L-Arginine deficiencies have on vasodilatory capacity by delivering specific Endothelin receptor agonists or supplemental L-Arginine via intradermal microdialysis.
Vasodilation will be elicited by local heating and changes in skin blood flux will be assessed via laser Doppler fluxmetry.
All changes in skin blood flux will be normalized and reported as a percentage of maximal flux.
|
Through study completion, an average of 1 Year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-0648
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on NG Nitro L Arginine Methyl Ester
-
The University of Texas at ArlingtonCompletedCardiovascular Diseases | Cardiovascular Risk Factor | VasoconstrictionUnited States
-
Anna Stanhewicz, PhDRecruiting
-
Washington University School of MedicineNational Institute on Aging (NIA)CompletedCardiovascular DiseasesUnited States
-
University Hospital, GrenobleCompletedHealthy VolunteersFrance
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Estrogen | MicrovasculatureUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Cancer Institute (NCI)TerminatedALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONUnited States
-
VA Office of Research and DevelopmentCompleted
-
US Department of Veterans AffairsCompletedHypotension | Spinal Cord InjuryUnited States
-
Cancer Research UKTerminatedUnspecified Adult Solid Tumor, Protocol SpecificUnited Kingdom
-
Medical University of ViennaTerminatedOcular Physiology | Regional Blood FlowAustria